On December 31, 2025, Clearmind Medicine Inc., a biotech company based in Vancouver, Canada, and listed under the tickers Nasdaq: CMND and FSE: CWY0, revealed that it had received a notification from the Nasdaq Stock Market. The letter stated that the company had successfully met the minimum bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2). Clearmind is known for its focus on developing innovative neuroplastogen-derived therapeutics to address significant unmet healthcare needs.